Contact Us
Drug Search Results
More Filters [+]

Onapristone

Alternative Names: onapristone
Latest Update: 2024-09-10
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PR Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Arno
Company Location: FLEMINGTON NJ 08822
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Onapristone

Countries in Clinic: United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Breast Cancer|Clear Cell Adenocarcinoma|Endometrial Cancer|Endometrioid Carcinoma|Ovarian Cancer|Peritoneal Cancer|Serous Cystadenocarcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
20P.829

P2

Active, not recruiting

Endometrial Cancer|Endometrioid Carcinoma|Serous Cystadenocarcinoma|Clear Cell Adenocarcinoma

2024-12-31

ELONA

P2

Active, not recruiting

Breast Cancer

2024-12-31

57%
NCT03909152

P2

Completed

Ovarian Cancer|Endometrial Cancer|Endometrioid Carcinoma|Peritoneal Cancer

2024-09-03

Recent News Events

Date

Type

Title

06/01/2023

PubMed

 Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment.

03/15/2023

News Article

 Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

02/06/2023

News Article

 Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

01/31/2023

News Article

 Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

01/09/2023

News Article

 Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

10/01/2020

PubMed

 Onapristone Extended Release: Safety Evaluation from Phase I-II Studies with an Emphasis on Hepatotoxicity.

04/30/2020

PubMed

 Progesterone receptor promotes degradation of STAT2 to inhibit the interferon response in breast cancer.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions